Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure

Exclusion Criteria

• •1. patients had clinically apparent CNS metastases or carcinomatous meningitis
• •2. another active malignancy, or any history of other malignancy within the past 5 years except for nonmelanoma skin cancer and carcinoma in situ of the cervix
• •3. more than 3 weeks intervals between the last administration of the prior chemotherapy regimen and study entry
• •4. more than 4 weeks intervals between the last administration of the targeted therapy regimen and study entry
• •5. major surgery within the prior 6 weeks;
• •6. Pregnant or lactating women
• •7. tumor involvement of major blood vessels
• •8. uncontrolled intercurrent illness
• •9. A history of myocardial infarction or stroke within the last 6 months, uncontrolled hypertension, unstable angina
• •10. clinically significant cardiac disease (eg, congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication, or myocardial infarction)
• •11. urine protein ≥ 500 mg in 24 hours;
• •12. evidence of bleeding diathesis or coagulopathy
• •13. Patients on therapeutic doses of low-molecular weight heparin
• •14. Patients who received thrombolytic agents within the previous month or who required full-dose anticoagulation.